Fig. 2 | Signal Transduction and Targeted Therapy

Fig. 2

From: First-line treatment of anti-EGFR monoclonal antibody cetuximab β plus FOLFIRI versus FOLFIRI alone in Chinese patients with RAS/BRAF wild-type metastatic colorectal cancer: a randomized, phase 3 trial

Fig. 2

PFS and OS of patients in the two treatment groups. a Kaplan–Meier estimates of BIRC-assessed PFS in the FAS. b Kaplan–Meier estimates of OS in the FAS. Crosses denote censored patients. BIRC blinded independent review committee, CI confidence interval, FAS full analysis set, FOLFIRI irinotecan, fluorouracil, and leucovorin, HR hazard ratio, OS overall survival, PFS progression-free survival

Back to article page